

Merkel Cell Carcinoma - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MD91E31DE2CEN.html>

Date: June 2020

Pages: 535

Price: US\$ 2,000.00 (Single User License)

ID: MD91E31DE2CEN

Abstracts

Merkel Cell Carcinoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2020, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 28, 14, 1 and 6 respectively.

Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Merkel Cell Carcinoma - Overview

Merkel Cell Carcinoma - Therapeutics Development

Merkel Cell Carcinoma - Therapeutics Assessment

Merkel Cell Carcinoma - Companies Involved in Therapeutics Development

Merkel Cell Carcinoma - Drug Profiles

Merkel Cell Carcinoma - Dormant Projects

Merkel Cell Carcinoma - Discontinued Products

Merkel Cell Carcinoma - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Merkel Cell Carcinoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Merkel Cell Carcinoma - Pipeline by 4SC AG, H1 2020
Merkel Cell Carcinoma - Pipeline by Amgen Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Apcline SAS, H1 2020
Merkel Cell Carcinoma - Pipeline by Arcus Biosciences Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Bavarian Nordic A/S, H1 2020
Merkel Cell Carcinoma - Pipeline by BeiGene Ltd, H1 2020
Merkel Cell Carcinoma - Pipeline by bluebird bio Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Boston Biomedical Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Bristol-Myers Squibb Co, H1 2020
Merkel Cell Carcinoma - Pipeline by Checkpoint Therapeutics Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020
Merkel Cell Carcinoma - Pipeline by CytomX Therapeutics Inc, H1 2020
Merkel Cell Carcinoma - Pipeline by Dragonfly Therapeutics Inc, H1 2020
Merkel Cell Carcinoma - Dormant Projects, H1 2020
Merkel Cell Carcinoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Merkel Cell Carcinoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4SC AG

Amgen Inc

Apcure SAS

Arcus Biosciences Inc

Bavarian Nordic A/S

BeiGene Ltd

bluebird bio Inc

Boston Biomedical Inc

Bristol-Myers Squibb Co

Checkpoint Therapeutics Inc

CStone Pharmaceuticals Co Ltd

CytomX Therapeutics Inc

Dragonfly Therapeutics Inc

Eli Lilly and Co

Exelixis Inc

Excicure Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Genexine Inc

Harbin Gloria Pharmaceuticals Co Ltd

ImmunityBio Inc

Immunomic Therapeutics Inc

Incyte Corp
Kartos Therapeutics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Morphogenesis Inc
NantKwest Inc
Nektar Therapeutics
NextCure Inc
Novartis AG
Ocellaris Pharma Inc
OncoSec Medical Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
QBiotics Ltd
Replimune Ltd
RHEACELL GmbH & Co KG
Sotio AS
Spring Bank Pharmaceuticals Inc
Tarveda Therapeutics Inc

I would like to order

Product name: Merkel Cell Carcinoma - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MD91E31DE2CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MD91E31DE2CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970